Wealth Quarterback’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealth Quarterback’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-88	Closed	-$9.52K	–	1161
2019 Q4	$9.52K	Buy	+88	New	+$9.41K	0.01%	542

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Wealth Quarterback's ALXN Position: Q1 2020 in Review

Wealth Quarterback sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 88 shares — an estimated $9.52K sold.

Wealth Quarterback first reported a position in ALXN in Q4 2019 and held it in 1 quarter. The position peaked at $9.52K in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Wealth Quarterback reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Wealth Quarterback sold 88 Alexion Pharmaceuticals shares in Q1 2020, an estimated $9.52K.
Wealth Quarterback first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Wealth Quarterback's Alexion Pharmaceuticals position peaked at $9.52K in Q4 2019.
653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Wealth Quarterback's 13F filing for Q1 2020, filed 14 May 2020.